AbCellera launches $200M public offering of common stock

AbCellera Biologics Inc. (Nasdaq: ABCL) announced a proposed underwritten public offering of $200.0 million of its common shares and pre-funded warrants to purchase common shares, according to a company statement.

The Vancouver-based clinical-stage biotechnology company said all shares and pre-funded warrants are being offered by AbCellera. The offering is subject to market and other conditions, with no assurance provided as to whether, or when, it may be completed, or as to its final size or terms.

AbCellera said it intends to use net proceeds to fund research, development, and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and general corporate purposes.

Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are serving as joint book-running managers for the proposed offering.

The securities are being offered under a shelf registration statement on Form S-3ASR filed with the U.S. Securities and Exchange Commission on February 27, 2025, which automatically became effective upon filing.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Werewolf Therapeutics to merge with Ambros in $150M private placement
• ESS Tech closes $3.2M stock offering at $0.50 per share